作者: Xiaoping Su , Gabriel G. Malouf , Francisco J. Esteva
DOI: 10.1007/978-1-4614-7645-0_18
关键词:
摘要: Cancer research is receiving a tremendous boost from the technological advancements known as next-generation sequencing, which have enabled researchers to identify gene mutations that are highly recurrent in several different subtypes of cancer and discover new based on profile mutations. The ability then target specific genetic each tumor promise developing personalized treatments. Much effort needed before can be realized. One area supporting this estimating purity heterogeneity. Tumors removed patients contain mixture normal cells. As result, analyses related must include determination how much tumor’s genome sequence differs matched tissue result mutation. We explore estimation chapter discuss software named PurityEst uses major clones purity.